October 14, 2009 – On October 5, 2009, drug maker Bristol-Myers Squibb Co. announced that its new diabetes drug, Saxagliptin [Onglyza], has been approved for sale in the European Union’s (EU) 27 countries. Saxagliptin [Onglyza] is the first diabetes drug …

Bristol-Myers gets approval for its diabetes drug Saxagliptin [Onglyza] in the European Union (EU) Read more »